FDA Approves Hovilpri for Refractory HSV Lesions

Originally published by our sister publication Infectious Disease Special EditionBy Meaghan Lee CallaghanThe FDA has approved pritelivir (Hovilpri, Asahi Kasei) for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, famciclovir, or valacyclovir in immunocompromised adults.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller;